Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction
Edward L. Hannan, PhD*,*,
Michael Racz, PhD ,
Gary Walford, MD ,
David R. Holmes, MD ,
Robert H. Jones, MD||,
Samin Sharma, MD¶,
Stanley Katz, MD#,
Spencer B. King, III, MD, MACC**
* University at Albany, State University of New York, Albany, New York
New York State Department of Health, Albany, New York
St. Joseph’s Hospital, Syracuse, New York
Mayo Clinic, Rochester, Minnesota
|| Duke University Medical Center, Durham, North Carolina
¶ Mt. Sinai Medical Center, New York, New York
# North Shore-LIJ Health System, Manhasset, New York
** Fuqua Heart Center/Piedmont Hospital, Atlanta, Georgia.
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Risk-Adjusted Mortality
Risk-adjusted mortality following primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI): bare-metal stent (BMS) versus drug-eluting stent (DES).
|
|
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Adjusted Rates of Subsequent CABG
Adjusted rates of subsequent coronary artery bypass graft (CABG) following primary PCI for STEMI: BMS versus DES. Abbreviations as in Figure 1.
|
|
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Adjusted Rates of Subsequent PCI in Target Vessel
Adjusted rates of subsequent PCI in target vessel following primary PCI for STEMI: BMS versus DES. Abbreviations as in Figure 1.
|
|
|
